Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
Alnylam Pharmaceuticals (United States) · Max Planck Institute of Molecular Cell Biology and Genetics · +1 more institution
Abstract
Lipid nanoparticles (LNPs) have proven to be highly efficient carriers of short-interfering RNAs (siRNAs) to hepatocytes in vivo; however, the precise mechanism by which this efficient delivery occurs has yet to be elucidated. We found that apolipoprotein E (apoE), which plays a major role in the clearance and hepatocellular uptake of physiological lipoproteins, also acts as an endogenous targeting ligand for ionizable LNPs (iLNPs), but not cationic LNPs (cLNPs). The role of apoE was investigated using both in vitro studies employing recombinant apoE and in vivo studies in wild-type and apoE−/− mice. Receptor dependence was explored in vitro and in vivo using low-density lipoprotein receptor…
Citation impact
- FWCI
- 15.65
- Percentile
- 100%
- References
- 32
Authors
25Topics & keywords
- Asialoglycoprotein receptor
- Apolipoprotein E
- LDL receptor
- In vivo
- Endogeny
- Receptor
- In vitro
- Small interfering RNA